Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards To Pay Up To $690m For Cardioband-Maker Valtech

Executive Summary

The Cardioband system is a transcatheter annuloplasty device for repair of mitral and tricuspid valves that should be a natural fit with Edwards transcatheter mitral valve development program. Israel-based Valtech had a deal in September 2015 to be acquired by HeartWare for $900m, but that deal fell through after HeartWare investors protested.

Advertisement

Related Content

Starts & Stops: Valve Repair And Replacement Tech Continues To Attract R&D Investment
Abbott Launches Feasibility Trial Of Tricuspid Version Of MitraClip
Relentless Rise Of Transcatheter Tech: Heart Valve Repair Turns Back On Open Surgery
M&A Analysis: November Deal Making Hits Whole New Low
Edwards, Boston Sci Make TAVR Progress In Europe
Medtronic Ups Its Heart-Failure Competitive Strength With HeartWare Buy
Shareholders Compel HeartWare To Drop Valtech Deal, Stay Focused On VADS
Transcatheter Mitral Valve Therapy: Opportunities And Challenges

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT104140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel